The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Full year result tracking to forecast: Co-operative Bank
Finance

Full year result tracking to forecast: Co-operative Bank

Tj FY2026 and core banking system replacement tracking in line.

RBNZ plan to cut AT1 capital layer wins cautious lender support
Finance

RBNZ plan to cut AT1 capital layer wins cautious lender support

Proposal to pare AT1 capital from prudential stacks wins cautious support from lenders.

Andy Macdonald 14 Oct 2025
Growth in new home loans eases in H1 2025: NZ Banking Association
Finance

Growth in new home loans eases in H1 2025: NZ Banking Association

Growth in new home loans eases in H1 2025 as NZ emerges from difficult economic climate.

Staff reporters 13 Oct 2025
ANZ NZ continues to hold market-leading position: ANZ Group
Finance

ANZ NZ continues to hold market-leading position: ANZ Group

ANZ NZ holds market-leading position, continues re-platforming: ANZ Group 

Staff reporters 13 Oct 2025